Navigation Links
Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
Date:12/13/2007

tistically significant, progressive and dose-dependent weight loss over a 12-week period. Lorcaserin was generally well tolerated at all doses and had no apparent effects on heart valves or pulmonary artery pressure. A scheduled review by an independent Echocardiographic Safety Monitoring Board of unblinded echocardiograms performed after patients completed six months of dosing in the BLOOM trial confirmed that differences, if any, in the rates of FDA-defined valvulopathy in patients treated with lorcaserin and in the control group did not meet the board's predetermined stopping criteria.

About Obesity

Obesity affects tens of millions of people in the United States and poses a serious long-term threat to their health and welfare. The number of overweight and obese people has substantially increased over the past several decades. Approximately two-thirds of all adults in the United States are obese or overweight, and medical and related costs of obesity were more than $123 billion according to a 2005 report by the International Diabetes Federation. Being obese or overweight is associated with increased risk of a number of conditions, including heart disease, stroke, diabetes, cancer and osteoarthritis. Medical treatment options for obese and overweight people currently are limited.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmace
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... (PRWEB) June 03, 2015 The ... a new world record by scaling CD-adapco’s flagship ... Blue Waters supercomputer. , STAR-CCM+ is a ... industries to stimulate innovation and lower product development ... and Blue Waters manufacturer Cray to push the ...
(Date:6/3/2015)... Global Stem Cells Group and ... to conduct Romania’s first ever stem cells harvesting and ... Miami-based Stem Cell Training, Inc., Cosmetic Surgeon Morad ... Marrow Stem Cell Training Course for medical professionals in ... practicing in Bucharest and Tel Aviv, Israel, and a ...
(Date:6/3/2015)... Intelligent Implant Systems, LLC is pleased ... 9,044,273, underpinning the Revolution™ Spinal System. Revolution™ is ... procedure by eliminating complicated reusable non-sterile instrument trays ... tray. The implants, designed specifically for this new ... Intelligent Implant Systems has additional patents on this ...
(Date:6/2/2015)... -- TapImmune, Inc. (OTCQB: TPIV), a clinical stage cancer ... agreement whereby the institutional investors will have the option ... Company up to $4.93M in near term funding, pending ... the restructured terms and subject to certain market conditions, ... result in a larger influx of capital to fund ...
Breaking Biology Technology:NCSA Scales CD-adapco’s STAR-CCM+ to New World Record of 102,000 Cores on Blue Waters 2NCSA Scales CD-adapco’s STAR-CCM+ to New World Record of 102,000 Cores on Blue Waters 3Global Stem Cells Group Announces First Stem Cell Training Course to Take Place in Romania 2Global Stem Cells Group Announces First Stem Cell Training Course to Take Place in Romania 3Intelligent Implant Systems Announces US Patent Attained for Revolution™ Spinal System 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 3
... -- China Yingxia,International, Inc. (OTC Bulletin Board: ... provider in the nutraceutical industry engaged in ... food,products, supplements, and personal care products in ... it will conduct a conference call, on,Friday, ...
... HORSHAM, Pa., Aug. 8 Centocor, Inc., today ... has extended the review,timeline for the Biologic License ... months to December 2008. The,application, filed by Centocor ... the treatment of adult patients with chronic moderate ...
... Aug. 8 Carna Biosciences, Inc. ("Carna"),is pleased ... with,Caliper Life Sciences, Inc. USA ("Caliper") on August ... set of discrete protein kinases aiding,the expansion of ... Kinase Selectivity Assay Kits. Caliper,s products and,services are ...
Cached Biology Technology:China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results 2FDA Extends Review Timeline for Ustekinumab Biologic License Application Three Months 2Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences 2
(Date:5/27/2015)... CLEVELAND , May 27, 2015 /PRNewswire/ ... in medication safety systems and image documentation ... provider of comprehensive, technologically-advanced automation solutions, is ... art integration. The Codonics® Safe Label System® ... used in conjunction with the Omnicell Anesthesia ...
(Date:5/25/2015)... 25, 2015  Australia,s market for wearable technologies is ... saw the advent of several trials and prototypes. The ... is expected to ignite interest in wearables as well ... Australia . This in turn will spur greater ... new partnerships amongst vendors and distributors. ...
(Date:5/22/2015)... , May 22, 2015 According ... by Solution (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, ... (Government and Utilities, Consumer and Home) - Global Forecast ... grow from $2.77 Billion in 2015 to $6.19 Billion ... Browse 79 market data Tables and   43 ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3
... American Chemical Society (ACS) News Service Weekly press package ... and Chemical & Engineering News. With more than 160,000 ... cite the individual journal, or the American Chemical Society, ... ARTICLE #1 FOR IMMEDIATE RELEASE Vaccine-like ...
... the October 1 issue of G&D, Dr. Guillermo ... colleagues present new evidence to resolve a century-old ... vasculature. Understanding the development of the lymphatic vasculature ... health (mediating immunity and maintaining tissue fluid levels) ...
... presents research on the genetic make-up and biology of ... better diagnosis and treatment of the diarrhea disease giardiasis, ... may also bring an understanding of several vital biological ... parasite that exists all over the world and causes ...
Cached Biology News:American Chemical Society's Weekly PressPac -- Sept. 26, 2007 2American Chemical Society's Weekly PressPac -- Sept. 26, 2007 3American Chemical Society's Weekly PressPac -- Sept. 26, 2007 4American Chemical Society's Weekly PressPac -- Sept. 26, 2007 5American Chemical Society's Weekly PressPac -- Sept. 26, 2007 6American Chemical Society's Weekly PressPac -- Sept. 26, 2007 7American Chemical Society's Weekly PressPac -- Sept. 26, 2007 8New Swedish research hope for millions of sufferers 2
...
... Immunogen: Synthetic Peptide: M(1) E F ... G P P T M D L E(19) ... mouse cells.,PA1-072 has been successfully used in Western ... detects an ~86 kDa protein representing Mint3 from ...
... The PolarScreen Androgen Receptor (AR) Competitor Assay ... for studying and screening potential AR ligands ... rat AR ligand binding domain protein tagged ... a novel, selective fluorescent androgen ligand (Fluormone ...
... offers bespoke, cost-effective solutions for complex protein processing and ... and experience to help you develop a solution to ... , ... transfer all methodology to your ...
Biology Products: